Novartis receives European Commission approval for self-administration of Xolair ® across all indications

Novartis today announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment. With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU. (Source: World Pharma News)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2rB4rWc